FDA Accepts ANDA for Dextromethorphan Hydrobromide and Quinidine Sulfate by Sun Pharma
The FDA's acceptance of Sun Pharma's ANDA for Dextromethorphan Hydrobromide and Quinidine Sulfate signifies a potential shift in the competitive landscape of the cough suppressant market. Portfolio teams must evaluate the implications for market share and strategize accordingly to mitigate risks from increased competition.
Company
Sun Pharma
Asset
FDA
Indication
Neurology / Cough Suppressant
Status
Approved
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The FDA's acceptance of Sun Pharma's ANDA for Dextromethorphan Hydrobromide and Quinidine Sulfate signifies a potential shift in the competitive landscape of the cough suppressant market. Portfolio teams must evaluate the implications for market share and strategize accordingly to mitigate risks from increased competition.
Why it matters
The FDA's acceptance of Sun Pharma's ANDA for Dextromethorphan Hydrobromide and Quinidine Sulfate signifies a potential shift in the competitive landscape of the cough suppressant market. Portfolio teams must evaluate the implications for market share and strategize accordingly to mitigate risks from increased competition.
What changed
Regulatory Approval
Analysis
The FDA has accepted the Abbreviated New Drug Application (ANDA) for Dextromethorphan Hydrobromide and Quinidine Sulfate submitted by Sun Pharma.
The FDA's acceptance of Sun Pharma's ANDA for Dextromethorphan Hydrobromide and Quinidine Sulfate signifies a potential shift in the competitive landscape of the cough suppressant market. Portfolio teams must evaluate the implications for market share and strategize accordingly to mitigate risks from increased competition.
Monitor the timeline for final approval and market entry, as well as competitor responses.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.